Open AccessJournal Article
Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for non-small cell lung cancer.
Takashi Nakashima,Cheng-long Huang,Dage Liu,Kotaro Kameyama,Daiki Masuya,Masaki Ueno,Reiji Haba,Hiroyasu Yokomise +7 more
Reads0
Chats0
TLDR
It is demonstrated that intratumoral VEGF-A expression is one of the significant prognostic factors in patients with adenocarcinomas, and that intrumoral V EGF-C expression isone of thesignificant prognostic Factors in patientsWith squamous cell carcinomas.Abstract:
BACKGROUND Understanding and controlling angiogenesis and lymphangiogenesis could lead to effective strategies for cancer treatment. The aim of our study was to clarify the clinical value of vascular endothelial growth factor-A (VEGF-A) and VEGF-C in non-small cell lung cancer (NSCLC). MATERIAL/METHODS One hundred and fifty-three patients with NSCLCs were studied to investigate intratumoral expression of VEGF-A and VEGF-C by immunohistochemistry. Simultaneously, we evaluated tumor angiogenesis using CD34 immunostaining. RESULTS Seventy-eight carcinomas (51.0%) were VEGF-A-positive, and 64 carcinomas (41.8%) were VEGF-C-positive. There was no correlationship between VEGF-A expression and VEGF-C expression in NSCLCs. The frequency of hypervascular tumors was significantly higher in VEGF-A-positive NSCLCs than in VEGF-A-negative NSCLCs (p=0.0442), while there was no correlation between intratumoral VEGF-C expression status and tumor vascularity. Concerning survival of NSCLC patients, intratumoral expression of VEGF-A was one of the significant prognostic factors in NSCLC patients (relative risk=2.012, p=0.0101), especially in patients with adenocarcinomas (relative risk=3.816, p=0.0025). On the other hand, intratumoral expression VEGF-C was one of the significant prognostic factors in patients with squamous cell carcinomas (relative risk=3.946, p=0.0143). CONCLUSIONS The present study demonstrated that intratumoral VEGF-A expression is one of the significant prognostic factors in patients with adenocarcinomas, and that intratumoral VEGF-C expression is one of the significant prognostic factors in patients with squamous cell carcinomas. These different functions of the VEGF family in relation to tumor histology might reflect the clinical behaviors of NSCLCs.read more
Citations
More filters
Biology and Current Status of Clinical Applications in Cardiovascular Medicine
TL;DR: The biology and effects of VEGFs as well as the current status of clinical applications and future perspectives of the therapeutic use of V EGFs in cardiovascular medicine are reviewed.
Journal ArticleDOI
Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.
TL;DR: Angiogenic factors are poor prognostic indicators for tumour aggressiveness and survival in NSCLC and assessments of circulating levels of VEGF and possibly bFGF may be valuable future tools for treatment planning and monitoring of treatment effect and relapse.
Journal ArticleDOI
Immunohistochemical markers of prognosis in non‐small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation
TL;DR: A guideline for a multi-phase approach for conducting future studies on prognostic immunohistochemistry markers is proposed here and Cyclin E, vascular endothelial growth factor A, p16INK4A, p27kip1 and β-catenin are promising candidates, but require further study in large randomised clinical trial samples by using standardised assays and scoring systems.
Journal ArticleDOI
Lymphangiogenesis Correlates with Lymph Node Metastasis, Prognosis, and Angiogenic Phenotype in Human Non–Small Cell Lung Cancer
Ferenc Rényi-Vámos,József Tóvári,János Fillinger,Jozsef Timar,Sándor Paku,István Kenessey,Gyula Ostoros,László Agócs,Ibolya Soltesz,Balazs Dome +9 more
TL;DR: Tumor lymphangiogenesis is revealed as a novel prognostic indicator for the risk of lymph node metastasis in NSCLC and provides the first evidence that nonangiogenic NSCLCs mainly co-opt host tissue lymphatics during their growth, in contrast to most of the angiogenic tumors, which expand with concomitant lymphang iogenesis.
Journal ArticleDOI
Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D.
Yasuyoshi Miyata,Shigeru Kanda,Kojiro Ohba,Koichiro Nomata,Yasushi Hayashida,Jiro Eguchi,Tomayoshi Hayashi,Hiroshi Kanetake +7 more
TL;DR: It is suggested that LVD and MVD are useful tools for the selection of postoperative management and treatment strategies in patients with bladder cancer and are regulated by VEGF-C and/or V EGF-D.